$CYTK
CYTOKINETICS INC

2021 Q4 Form 10-K Financial Statement

#000156459022007218 Filed on February 25, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $55.60M $70.43M $6.720M
YoY Change 727.38% 26.15% 28.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $33.81M $96.80M $13.91M
YoY Change 143.03% 83.34% 31.47%
% of Gross Profit
Research & Development $43.50M $159.9M $29.22M
YoY Change 48.86% 64.97% 59.41%
% of Gross Profit
Depreciation & Amortization $734.0K $2.276M $470.0K
YoY Change 56.17% 24.3% 20.51%
% of Gross Profit
Operating Expenses $77.30M $256.7M $43.13M
YoY Change 79.23% 71.42% 49.14%
Operating Profit -$186.3M
YoY Change 98.33%
Interest Expense -$8.866M $16.44M -$7.520M
YoY Change 17.9% 2.99% 8.51%
% of Operating Profit
Other Income/Expense, Net $331.0K
YoY Change -93.79%
Pretax Income -$30.57M -$215.3M -$43.93M
YoY Change -30.41% 69.14% 43.37%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$30.57M -$215.3M -$43.93M
YoY Change -30.41% 69.14% 43.37%
Net Earnings / Revenue -54.98% -305.7% -653.72%
Basic Earnings Per Share -$2.80
Diluted Earnings Per Share -$363.2K -$2.800M -$680.9K
COMMON SHARES
Basic Shares Outstanding 76.89K
Diluted Shares Outstanding 76.89K

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $471.6M $471.6M $464.1M
YoY Change 1.63% 1.62% 106.15%
Cash & Equivalents $112.7M $112.7M $82.99M
Short-Term Investments $359.0M $359.0M $381.1M
Other Short-Term Assets $12.22M $12.22M $5.700M
YoY Change 114.3% 114.3% 62.86%
Inventory
Prepaid Expenses
Receivables $51.82M $51.82M $4.420M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $535.7M $535.7M $474.2M
YoY Change 12.96% 12.96% 102.87%
LONG-TERM ASSETS
Property, Plant & Equipment $73.27M $146.4M $13.35M
YoY Change 449.01% 547.83% 194.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $152.1M $152.1M $37.00M
YoY Change 310.95% 310.95% -13.35%
Other Assets $7.188M $7.188M $6.358M
YoY Change 13.05%
Total Long-Term Assets $305.6M $305.6M $59.58M
YoY Change 412.99% 412.83% 6.28%
TOTAL ASSETS
Total Short-Term Assets $535.7M $535.7M $474.2M
Total Long-Term Assets $305.6M $305.6M $59.58M
Total Assets $841.3M $841.3M $533.8M
YoY Change 57.61% 57.61% 84.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.09M $21.09M $8.050M
YoY Change 161.95% 160.33% -1.35%
Accrued Expenses $34.37M $49.23M $19.32M
YoY Change 77.94% 122.77% 59.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $500.0K $0.00
YoY Change
Total Short-Term Liabilities $71.86M $71.86M $31.20M
YoY Change 130.33% 130.32% 19.89%
LONG-TERM LIABILITIES
Long-Term Debt $47.37M $143.6M $46.21M
YoY Change 2.51% 5.85% 2.57%
Other Long-Term Liabilities $4.457M $382.0M $0.00
YoY Change 50.67% -100.0%
Total Long-Term Liabilities $51.82M $525.6M $46.21M
YoY Change 12.15% 35.05% 2.57%
TOTAL LIABILITIES
Total Short-Term Liabilities $71.86M $71.86M $31.20M
Total Long-Term Liabilities $51.82M $525.6M $46.21M
Total Liabilities $597.5M $597.5M $420.4M
YoY Change 42.11% 42.12% 39.79%
SHAREHOLDERS EQUITY
Retained Earnings -$1.208B -$992.3M
YoY Change 21.7% 14.72%
Common Stock $1.452B $1.106B
YoY Change 31.37% 29.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $243.9M $243.9M $113.4M
YoY Change
Total Liabilities & Shareholders Equity $841.3M $841.3M $533.8M
YoY Change 57.61% 57.61% 84.19%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$30.57M -$215.3M -$43.93M
YoY Change -30.41% 69.14% 43.37%
Depreciation, Depletion And Amortization $734.0K $2.276M $470.0K
YoY Change 56.17% 24.3% 20.51%
Cash From Operating Activities -$44.74M -$142.5M $52.15M
YoY Change -185.79% -1693.43% -373.61%
INVESTING ACTIVITIES
Capital Expenditures -$17.75M -$48.87M -$6.550M
YoY Change 171.05% -542.2% 400.0%
Acquisitions
YoY Change
Other Investing Activities $65.09M -$98.91M -$167.1M
YoY Change -138.96% -46.67% 60.7%
Cash From Investing Activities $47.34M -$147.8M -$173.6M
YoY Change -127.26% -24.8% 64.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities 19.51M 320.0M 3.640M
YoY Change 435.88% 36.67% -96.99%
NET CHANGE
Cash From Operating Activities -44.74M -142.5M 52.15M
Cash From Investing Activities 47.34M -147.8M -173.6M
Cash From Financing Activities 19.51M 320.0M 3.640M
Net Change In Cash 22.10M 29.68M -117.8M
YoY Change -118.76% -36.24% 3570.72%
FREE CASH FLOW
Cash From Operating Activities -$44.74M -$142.5M $52.15M
Capital Expenditures -$17.75M -$48.87M -$6.550M
Free Cash Flow -$26.98M -$93.63M $58.70M
YoY Change -145.97% 4339.45% -430.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 dei Entity Public Float
EntityPublicFloat
1443000000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1207600000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssets
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1207600000
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Redwood City, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112666000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82985000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
358972000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
381075000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
51819000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4420000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12215000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5741000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
535672000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
474221000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
152050000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
36954000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73271000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13346000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
73138000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2924000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7188000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6358000
CY2021Q4 us-gaap Assets
Assets
841319000
CY2020Q4 us-gaap Assets
Assets
533803000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
21087000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8050000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34370000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19315000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
14863000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2785000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1540000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1049000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71860000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31199000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
47367000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
46209000
CY2021Q4 cytk Convertible Notes Net
ConvertibleNotesNet
95471000
CY2020Q4 cytk Convertible Notes Net
ConvertibleNotesNet
89504000
CY2021Q4 cytk Liabilities Related To Revenue Participation Right Purchase Agreement Net
LiabilitiesRelatedToRevenueParticipationRightPurchaseAgreementNet
179072000
CY2020Q4 cytk Liabilities Related To Revenue Participation Right Purchase Agreement Net
LiabilitiesRelatedToRevenueParticipationRightPurchaseAgreementNet
166068000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
87000000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
87000000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
112229000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
440000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4457000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Liabilities
Liabilities
597456000
CY2020Q4 us-gaap Liabilities
Liabilities
420420000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113383000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
841319000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
533803000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
70428000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84799542
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84799542
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71015183
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71015183
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
84000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
70000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1452268000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1105470000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-869000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
149000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1207620000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-992306000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
243863000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
55828000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26868000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159938000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96951000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86125000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
96803000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
52820000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39610000
CY2021 us-gaap Operating Expenses
OperatingExpenses
256741000
CY2020 us-gaap Operating Expenses
OperatingExpenses
149771000
CY2019 us-gaap Operating Expenses
OperatingExpenses
125735000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-186313000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-93943000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-98867000
CY2021 us-gaap Interest Expense
InterestExpense
16440000
CY2020 us-gaap Interest Expense
InterestExpense
15963000
CY2019 us-gaap Interest Expense
InterestExpense
6623000
CY2021 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
12892000
CY2020 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
22713000
CY2019 cytk Non Cash Interest Expense On Liability Related To Sale Of Future Royalties
NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
20737000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
331000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5329000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4535000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-215314000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-127290000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-121692000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.80
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.97
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.11
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
76886
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
64524
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57575
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1018000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-530000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
179000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-216332000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127820000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-121513000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-530000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
36214000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1108000
CY2019 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
732000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
185000
CY2019 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
49477000
CY2019 cytk Adjustments To Additional Paid In Capital Capped Call Options Associated With Convertible Notes
AdjustmentsToAdditionalPaidInCapitalCappedCallOptionsAssociatedWithConvertibleNotes
13386000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10759000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7611000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2020 cytk Adjustment To Additional Paid In Capital To Section16 B Claim Settlement
AdjustmentToAdditionalPaidInCapitalToSection16BClaimSettlement
2151000
CY2020 cytk Stock Issue During Period Private Placement Value
StockIssueDuringPeriodPrivatePlacementValue
36437000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1509000
CY2020 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2255000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
184000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17620000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-127290000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113383000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11020000
CY2021 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4449000
CY2021 cytk Net Share Settlements
NetShareSettlements
-418000
CY2021 cytk Stock Issue During Period Private Placement Value
StockIssueDuringPeriodPrivatePlacementValue
15144000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1778000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26832000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1018000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-215314000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
243863000
CY2021 us-gaap Profit Loss
ProfitLoss
-215314000
CY2020 us-gaap Profit Loss
ProfitLoss
-127290000
CY2019 us-gaap Profit Loss
ProfitLoss
-121692000
CY2021 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
13004000
CY2020 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
22792000
CY2019 cytk Non Cash Interest Expense On Liabilities Related To Revenue Participant Right Purchase Agreement
NonCashInterestExpenseOnLiabilitiesRelatedToRevenueParticipantRightPurchaseAgreement
20737000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
26832000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
17620000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
10759000
CY2021 cytk Non Cash Lease Expense
NonCashLeaseExpense
7361000
CY2020 cytk Non Cash Lease Expense
NonCashLeaseExpense
4221000
CY2019 cytk Non Cash Lease Expense
NonCashLeaseExpense
3552000
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2844000
CY2020 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2019 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2276000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1831000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1293000
CY2021 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2020 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
573000
CY2019 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0
CY2021 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
4894000
CY2020 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-1194000
CY2019 cytk Interest Receivable And Amortization On Investments
InterestReceivableAndAmortizationOnInvestments
-2587000
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
7125000
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
6640000
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
919000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
47399000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-743000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2932000
CY2021 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0
CY2020 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
0
CY2019 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-4554000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7381000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5162000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3862000
CY2021 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1055000
CY2020 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-110000
CY2019 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4396000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
15060000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7117000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2168000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
87000000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2021 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
43472000
CY2020 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4692000
CY2019 cytk Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3876000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
3649000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-142522000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8943000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90907000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
525042000
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
435825000
CY2019 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
277883000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
422837000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
247301000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
202599000
CY2021 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3300000
CY2020 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3061000
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
3196000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2619000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-196515000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-74707000
CY2021 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
296905000
CY2020 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
188883000
CY2019 cytk Proceeds From Issuance Of Underwritten Public Offering Of Common Stock Net
ProceedsFromIssuanceOfUnderwrittenPublicOfferingOfCommonStockNet
0
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
15144000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
36225000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7931000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6865000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1393000
CY2021 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
0
CY2020 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
2151000
CY2019 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
0
CY2021 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2020 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2019 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
1710000
CY2021 cytk Proceeds From Convertible Notes Net Of Debt Discount And Issuance Costs
ProceedsFromConvertibleNotesNetOfDebtDiscountAndIssuanceCosts
0
CY2020 cytk Proceeds From Convertible Notes Net Of Debt Discount And Issuance Costs
ProceedsFromConvertibleNotesNetOfDebtDiscountAndIssuanceCosts
0
CY2019 cytk Proceeds From Convertible Notes Net Of Debt Discount And Issuance Costs
ProceedsFromConvertibleNotesNetOfDebtDiscountAndIssuanceCosts
133860000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36214000
CY2021 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
0
CY2020 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
0
CY2019 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
13386000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
319980000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234124000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
159791000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29681000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
46552000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
82985000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36433000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
9175000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
9620000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
4059000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
80395000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1106000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10687000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1294000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11982000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-215300000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-142500000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
623700000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
501000000.0
CY2021 cytk Cash Requirements Term
CashRequirementsTerm
P12M
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. We evaluate our estimates on an ongoing basis. We base our estimates on our historical experience and also on assumptions that we believe are reasonable; however, actual results could significantly differ from those estimates.</p>
CY2021 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2020 us-gaap Debt Securities Available For Sale Gain Loss
DebtSecuritiesAvailableForSaleGainLoss
0
CY2021Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
47400000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, investments, and accounts receivable.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash, cash equivalents and investments are invested in deposits with two major financial institutions in the United States. Deposits in these banks may exceed the amount of insurance provided on such deposits. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our exposure to credit risk associated with non-payment is limited to Astellas Pharma Inc. for co-funding one-third of the out-of-pocket clinical development costs which may be incurred in connection with Cytokinetics’ Phase 3 clinical trial, COURAGE-ALS, of reldesemtiv in ALS up to a maximum contribution by Astellas of $12.0 million, to our strategic partner in the People’s Republic of China (including the Hong Kong and Macau Special Administration Districts) (“China”) and Taiwan, Ji Xing Pharmaceuticals Limited<span style="Background-color:#FFFFFF;color:#000000;"> (“Ji Xing”), and Royalty Pharma Investments ICAV (“RPI ICAV”), to whom we sold a revenue interest in our net sales of pharmaceutical products containing aficamten under a revenue interest purchase agreement, dated January 7, 2022 (the “RP Aficamten RPA”), as further described in Note 11 below.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug candidates we develop may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or other regulatory agencies prior to commercial sales. There can be no assurance that our drug candidates will receive any of the required approvals or clearances. If we were to be denied approval, or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p>
CY2021Q4 cytk Number Of Financial Institutions
NumberOfFinancialInstitutions
2
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13346000
CY2021Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
618900000
CY2021Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
179100000
CY2021 us-gaap Depreciation
Depreciation
2300000
CY2020 us-gaap Depreciation
Depreciation
1800000
CY2019 us-gaap Depreciation
Depreciation
1300000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27519000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26362000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25465000
CY2020 cytk Milestone Payments Received Under Arrangements
MilestonePaymentsReceivedUnderArrangements
2500000
CY2021Q3 cytk Milestone Payments Received Under Arrangements
MilestonePaymentsReceivedUnderArrangements
5000000.0
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
626959000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
498079000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000000.0
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
5300000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
4500000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
89460000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37987000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16189000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24641000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73271000
CY2021Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
13872000
CY2020Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
6124000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14930000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11787000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5568000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1404000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34370000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19315000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
900000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000
CY2019 cytk Payment For Purchase Of Capped Call Options Associated With Convertible Notes
PaymentForPurchaseOfCappedCallOptionsAssociatedWithConvertibleNotes
13400000
CY2019Q4 cytk Capped Call Transactions Cap Price
CappedCallTransactionsCapPrice
14.07
CY2019Q4 cytk Capped Call Premium Percentage Of Sale Price Of Common Stock
CappedCallPremiumPercentageOfSalePriceOfCommonStock
0.70
CY2020Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
166068000
CY2019Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
143276000
CY2021 cytk Interest Accretion
InterestAccretion
12892000
CY2020 cytk Interest Accretion
InterestAccretion
22713000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
112000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
79000
CY2021Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
179072000
CY2020Q4 cytk Liability Related To Sale Of Future Royalties Net
LiabilityRelatedToSaleOfFutureRoyaltiesNet
166068000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7759012
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1944562
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.59
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.27
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
234054
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.06
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8501949
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.02
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
2513350
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
22.43
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.01
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
296146
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.56
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9372959
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.35
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
302100000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5828902
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.99
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
207400000
CY2021Q4 cytk Lease Obligations For Finance Leases Not Yet Commenced
LeaseObligationsForFinanceLeasesNotYetCommenced
1900000
CY2021 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
23100000
CY2020 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
5700000
CY2019 cytk Operating And Finance Lease Expense
OperatingAndFinanceLeaseExpense
5100000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 cytk Proceeds From Claims Settlements
ProceedsFromClaimsSettlements
2200000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
165424
CY2021Q4 cytk Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
7.25
CY2021 cytk Expiry Period Of Warrants After Date Of Issuance
ExpiryPeriodOfWarrantsAfterDateOfIssuance
P10Y
CY2021 cytk Sales Commission As Percentage Of Gross Proceeds
SalesCommissionAsPercentageOfGrossProceeds
0.030
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1305000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26832000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17620000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10759000
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.76
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
23065
CY2021 cytk Warrant Expiration Period
WarrantExpirationPeriod
2029-05
CY2021 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2800000
CY2021Q4 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P3Y
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
15611000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
513000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
17060000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
479000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
17620000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
479000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
18199000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
18799000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
146193000
CY2021Q4 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
233482000
CY2021Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1471000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
106390000
CY2021Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
166000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
127092000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.03
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.02
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.04
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.24
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.23
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.30
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.02
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.01
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
181977000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
162514000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
77366000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
71976000
CY2021Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
38302000
CY2020Q4 cytk Deferred Tax Assets Liability Related To Sale Of Future Royalties
DeferredTaxAssetsLiabilityRelatedToSaleOfFutureRoyalties
36989000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
15409000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
10876000
CY2021Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
1115000
CY2020Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
2370000
CY2021Q4 cytk Deferred Tax Assets Long Term Lease Liability
DeferredTaxAssetsLongTermLeaseLiability
26223000
CY2020Q4 cytk Deferred Tax Assets Long Term Lease Liability
DeferredTaxAssetsLongTermLeaseLiability
718000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
18608000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
0
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
746000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
359000000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
286189000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
7664000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2021Q4 cytk Deferred Tax Liabilities Accounting Method Change
DeferredTaxLiabilitiesAccountingMethodChange
0
CY2020Q4 cytk Deferred Tax Liabilities Accounting Method Change
DeferredTaxLiabilitiesAccountingMethodChange
927000
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
15643000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
651000
CY2021Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
8296000
CY2020Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
9832000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31603000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
11410000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
327397000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
274779000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
52600000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
28900000
CY2021 cytk Research And Development Federal Tax Credit Carryforwards Expiration Date Year
ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear
2021
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10522000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9922000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9475000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
29000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
802000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
603000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
447000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11295000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10522000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9922000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
10300000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
9600000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
9100000

Files In Submission

Name View Source Status
0001564590-22-007218-index-headers.html Edgar Link pending
0001564590-22-007218-index.html Edgar Link pending
0001564590-22-007218.txt Edgar Link pending
0001564590-22-007218-xbrl.zip Edgar Link pending
cytk-10k_20211231.htm Edgar Link pending
cytk-10k_20211231_htm.xml Edgar Link completed
cytk-20211231.xsd Edgar Link pending
cytk-20211231_cal.xml Edgar Link unprocessable
cytk-20211231_def.xml Edgar Link unprocessable
cytk-20211231_lab.xml Edgar Link unprocessable
cytk-20211231_pre.xml Edgar Link unprocessable
cytk-ex1014_173.htm Edgar Link pending
cytk-ex1015_102.htm Edgar Link pending
cytk-ex1016_101.htm Edgar Link pending
cytk-ex1017_100.htm Edgar Link pending
cytk-ex1018_99.htm Edgar Link pending
cytk-ex1020_97.htm Edgar Link pending
cytk-ex1021_98.htm Edgar Link pending
cytk-ex104_103.htm Edgar Link pending
cytk-ex231_9.htm Edgar Link pending
cytk-ex311_10.htm Edgar Link pending
cytk-ex312_13.htm Edgar Link pending
cytk-ex313_11.htm Edgar Link pending
cytk-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gcbzmab0wiut000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending